Sjogren syndrome

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…

This phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…

This study tests if a new 2mL auto-injector or pre-filled syringe delivers the same amount of the drug ianalumab into the body as the current 1mL syringe. About 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus will receive the drug both ways to compare how much g…

This early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…

This study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no…

This phase 3 study tests whether the drug ianalumab can reduce disease activity in people with active Sjogren's syndrome. About 275 adults with the condition will receive either ianalumab or a placebo shot under the skin. The main goal is to see if the drug improves symptoms and …

This phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …

This phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…

This phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…

This Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…

This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This Phase 3 trial tests dazodalibep, a drug given by IV, in 651 people with moderate-to-severe Sjögren's syndrome. The goal is to see if it reduces disease activity and improves symptoms like dryness and fatigue. Participants receive either the drug or a placebo, and researchers…

This early-phase trial is testing the safety of tofacitinib (Xeljanz), a drug already used for rheumatoid arthritis, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants take the drug or a placebo daily for 168 days. The goal is to see if the drug is safe and toler…

This study compares using cyclosporine eye drops alone versus combining them with absorbable punctal plugs for dry eye caused by Sjögren's syndrome. Thirty participants will receive the drops in both eyes and a plug in one eye to see if the combination improves symptoms better. T…

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This study tests an experimental drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, an autoimmune disease causing dryness, fatigue, and pain. Participants receive either the drug or a placebo to see if it improves symptoms like dry eyes and mouth. T…

This study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…

This study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…

This study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…

This study looks at whether changes in gut bacteria can affect Sjögren's syndrome, an autoimmune disease causing dry eyes, dry mouth, and fatigue. Researchers will measure blood markers of gut leakage in 50 adults with Sjögren's to see if these markers change when disease activit…

This study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…

This study offers free vision screenings to underserved adults over 40 living in affordable housing in Harlem and Washington Heights. The goal is to find eye problems like glaucoma, cataracts, and diabetic retinopathy early and connect people with follow-up care. About 749 partic…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…